Share Email Print
cover

Proceedings Paper

Fluorescence imaging of experimental rheumatoid arthritis in vivo using a fast flying-spot scanner
Author(s): J. Berger; J. Voigt; F. Seifert; B. Ebert; R. Macdonald; I. Gemeinhardt; O. Gemeinhardt; J. Schnorr; M. Taupitz; A. Vater; S. Vollmer; K. Licha; M. Schirner
Format Member Price Non-Member Price
PDF $14.40 $18.00

Paper Abstract

We have developed a flying-spot scanner for fluorescence imaging of rheumatoid arthritis in the near infrared (NIR) spectral range following intravenous administration of contrast agents. The new imaging system has been characterized with respect to linearity, dynamic range and spatial resolution with the help of fluorescent phantoms. In vivo experiments were performed on an animal model of rheumatoid arthritis. Finally, NIR-fluorescence images of early stages of joint inflammation have been compared with findings from contrast enhanced MR imaging and histology.

Paper Details

Date Published: 18 July 2007
PDF: 6 pages
Proc. SPIE 6631, Novel Optical Instrumentation for Biomedical Applications III, 66310U (18 July 2007); doi: 10.1117/12.728307
Show Author Affiliations
J. Berger, Physikalisch-Technische Bundesanstalt (Germany)
J. Voigt, Physikalisch-Technische Bundesanstalt (Germany)
F. Seifert, Physikalisch-Technische Bundesanstalt (Germany)
B. Ebert, Physikalisch-Technische Bundesanstalt (Germany)
R. Macdonald, Physikalisch-Technische Bundesanstalt (Germany)
I. Gemeinhardt, Charité-Universitätsmedizin Berlin (Germany)
O. Gemeinhardt, Institute of Veterinary Anatomy, Freie Univ. Berlin (Germany)
J. Schnorr, Charité-Universitätsmedizin Berlin (Germany)
M. Taupitz, Charité-Universitätsmedizin Berlin (Germany)
A. Vater, Bayer Schering Pharma AG (Germany)
S. Vollmer, Bayer Schering Pharma AG (Germany)
K. Licha, Bayer Schering Pharma AG (Germany)
M. Schirner, Bayer Schering Pharma AG (Germany)


Published in SPIE Proceedings Vol. 6631:
Novel Optical Instrumentation for Biomedical Applications III
Christian D. Depeursinge, Editor(s)

© SPIE. Terms of Use
Back to Top